At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 19 enrolled
Drug / intervention
Apixaban +1 moredrug
Likely dose
Apixaban 10mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized Trial to Test the Effect of Rivaroxaban or Apixaban on Menstrual Blood Loss in Women
In Brief
A Phase 3 clinical trial evaluating Apixaban and Rivaroxaban for Venous Thromboembolism and Menstruation. Completed, enrolled 19 participants across 2 sites.
Detailed Summary
A large proportion of women with menstruating potential with newly diagnosed VTE or atrial fibrillation, treated with apixaban will have less menstrual blood loss than patients randomized to rivaroxaban.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVenous Thromboembolism, Menstruation
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedJul 2016
Enrollment StartSep 2016
Primary CompletionFeb 2020
TodayJul 2026
First PostedJul 12, 2016
Enrollment StartSep 1, 2016
Primary CompletionFeb 13, 2020
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 10.0 years ago
Interventions
Apixabandrug
10mg BID for 7 days, then 5mg BID for three months
Rivaroxabandrug
15mg BID for 7 days, then 20mg daily for three months